Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy.
作者信息
Danesh Melissa J, Mulvaney Patrick M, Murakami Naoka, Riella Leonardo V, Silk Ann W, Hanna Glenn J, Schmults Chrysalyne D
机构信息
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Division of Nephrology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
出版信息
Cancer Immunol Immunother. 2020 Sep;69(9):1937-1941. doi: 10.1007/s00262-020-02644-2. Epub 2020 Jun 25.
Abstract
摘要
相似文献
1
Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy.皮质类固醇对接受抗PD-1免疫治疗的肾移植患者同种异体移植保护的影响。
Cancer Immunol Immunother. 2020 Sep;69(9):1937-1941. doi: 10.1007/s00262-020-02644-2. Epub 2020 Jun 25.
2
Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy.帕博利珠单抗导致的严重排斥和移植物不耐受综合征，导致肾移植肾切除。
J Oncol Pharm Pract. 2021 Mar;27(2):470-476. doi: 10.1177/1078155220934160. Epub 2020 Jun 24.
3
Checkpoint blockade after kidney transplantation.肾移植后的检查点阻断
Eur J Cancer. 2018 Jun;96:111-114. doi: 10.1016/j.ejca.2018.03.019. Epub 2018 Apr 26.
4
Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature.安全给予抗 PD-1 抗体至肾移植受者：2 个临床病例与文献回顾。
J Immunother. 2017 Nov/Dec;40(9):341-344. doi: 10.1097/CJI.0000000000000188.
5
Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.硼替佐米、皮质类固醇、利妥昔单抗和血浆置换联合治疗晚期抗体介导的肾移植排斥反应后的持久肾脏反应
Clin Nephrol. 2018 Apr;89(4):252-259. doi: 10.5414/CN109278.
6
Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.新辅助程序性细胞死亡 1（PD-1）抑制剂治疗肝癌患者肝移植前：队列研究和文献复习。
Front Immunol. 2021 Jul 19;12:653437. doi: 10.3389/fimmu.2021.653437. eCollection 2021.
7
Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.肾移植患者接受抗PD1治疗后发生严重同种异体移植排斥反应和自身免疫性溶血性贫血
Transplantation. 2017 Sep;101(9):e291. doi: 10.1097/TP.0000000000001861.
8
Increased circulating follicular helper T cells with decreased programmed death-1 in chronic renal allograft rejection.慢性肾移植排斥反应中循环滤泡辅助性T细胞增加且程序性死亡-1减少。
BMC Nephrol. 2015 Nov 3;16:182. doi: 10.1186/s12882-015-0172-8.
9
The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.派姆单抗成功治疗肾移植受者转移性黑色素瘤。
Melanoma Res. 2020 Jun;30(3):321-324. doi: 10.1097/CMR.0000000000000651.
10
Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.PD-1通路抑制剂纳武单抗在一名患有恶性肿瘤的肾移植患者中的应用。
Am J Transplant. 2016 Aug;16(8):2496-7. doi: 10.1111/ajt.13786. Epub 2016 Apr 21.
引用本文的文献
1
Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits.肾移植患者的癌症免疫治疗：风险与益处之间的艰难平衡
Transpl Int. 2024 Nov 25;37:13204. doi: 10.3389/ti.2024.13204. eCollection 2024.
2
Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients - A Review of Potential Complications and Management Strategies.免疫检查点抑制剂治疗肾移植受者：潜在并发症及管理策略的综述
Transpl Int. 2024 Oct 16;37:13322. doi: 10.3389/ti.2024.13322. eCollection 2024.
3
Acute Allograft Rejection in Kidney Transplant Recipients Treated With Immune Checkpoint Inhibitors: An Educational Case Report.免疫检查点抑制剂治疗的肾移植受者急性同种异体移植排斥反应：一例教学病例报告
Can J Kidney Health Dis. 2024 Oct 21;11:20543581241289191. doi: 10.1177/20543581241289191. eCollection 2024.
4
Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies.免疫检查点抑制剂在患有晚期皮肤恶性肿瘤的实体器官移植受者中的应用。
Front Transplant. 2023 Oct 30;2:1284740. doi: 10.3389/frtra.2023.1284740. eCollection 2023.
5
Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system.同种异体移植物排斥反应后免疫检查点抑制剂在实体器官移植受者：从文献复习和药物警戒系统的安全性分析。
Cancer Med. 2023 Mar;12(5):5181-5194. doi: 10.1002/cam4.5394. Epub 2022 Dec 12.
6
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.实体器官移植受者的免疫检查点抑制剂：临床进展
Korean J Transplant. 2022 Jun 30;36(2):82-98. doi: 10.4285/kjt.22.0013. Epub 2022 Jun 3.
7
Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?免疫疗法与肾病谱：我们是否应该个体化治疗？
Front Med (Lausanne). 2022 Jun 14;9:906565. doi: 10.3389/fmed.2022.906565. eCollection 2022.
8
Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.免疫检查点抑制剂在实体器官移植受者中的应用：系统评价。
Interdiscip Sci. 2021 Dec;13(4):801-814. doi: 10.1007/s12539-021-00437-4. Epub 2021 Jun 21.
9
Immunotherapy use outside clinical trial populations: never say never?免疫疗法在临床试验人群之外的应用：永不言弃？
Ann Oncol. 2021 Jul;32(7):866-880. doi: 10.1016/j.annonc.2021.03.199. Epub 2021 Mar 24.
10
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.免疫检查点抑制剂在肾移植癌症患者中的安全性和疗效的多中心研究。
Kidney Int. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24.
本文引用的文献
1
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.免疫检查点抑制剂相关肾毒性：2020 更新版。
Kidney360. 2020 Jan 14;1(2):130-140. doi: 10.34067/KID.0000852019. eCollection 2020 Feb 27.
2
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.移植受者中检查点抑制剂的安全性和疗效：病例系列和文献系统评价。
Oncologist. 2020 Jun;25(6):505-514. doi: 10.1634/theoncologist.2019-0659. Epub 2020 Feb 11.
3
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.实体器官移植受者中癌症的检查点抑制剂治疗：机构经验和文献系统评价。
J Immunother Cancer. 2019 Apr 16;7(1):106. doi: 10.1186/s40425-019-0585-1.
4
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.mTOR 信号通路与 mTOR 抑制剂在实体肿瘤靶向治疗中的应用。
Int J Mol Sci. 2019 Feb 11;20(3):755. doi: 10.3390/ijms20030755.
5
Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.保存肾移植功能与PD-1通路抑制剂纳武单抗
N Engl J Med. 2017 Jan 12;376(2):191-192. doi: 10.1056/NEJMc1614298.
Zotero 插件